禮來(LLY.US)減肥藥獲得FDA批准
美國食品藥物管理局(FDA)周三(9日)批准備受期待的禮來公司(LLY.US)肥胖症治療藥物,揭開市場普遍預期或將會是歷史上最暢銷藥物之一的神秘面紗。
禮來公司的這款藥物將以Zepbound的名稱作為肥胖治療藥物銷售,目前已經以Mounjaro的名稱作為糖尿病治療藥物銷售,並將與諾和諾德(NVO.US)旗下肥胖藥物Wegovy直接競爭。
FDA周三表示,在一項試驗中,非糖尿病患者服用Zepbound 72周後體重減輕18%。該機構批准Zepbound用於肥胖成人或超重且患有至少一種與體重相關的疾病,如高血壓或高膽固醇的人。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.